Pharmaceutical company Amgen has just released more positive findings for denosumab, a new osteoporosis drug in development. The latest studies indicate that the medication, which would be given as injections twice a year, helped increase bone mass in the lumbar spine significantly over use of a placebo.
The research indicates that it can help patients with low bone mass as well as more advanced osteoporosis. Denosumab is also being studied for use in the treatment of cancer-related bone diseases. Amgen hopes to have all the data needed - including a fracture within months - to submit the drug for FDA approval for osteoporosis by the end of the year.
Read more about Denosumab at http://www.amgen.com/media/media_pr_detail.jsp?year=2008&releaseID=1125003, or at the Journal of Clinical Endocrinology and Metabolism at http://jcem.endojournals.org/cgi/gca?allch=&SEARCHID=1&FULLTEXT=denosumab&FIRSTINDEX=0&hits=10&RESULTFORMAT=&gca=jcem%3Bjc.2007-2814v1
Published On: April 02, 2008